DiPALS study survival medians were 28 months (pacer) , 45 months (NIV) . . . normal NIV survival is usually exceeds 36 months . . . thus, the question, 'Why were both results so poor?' remains open. RespiStimALS results were similar to the results used by the United States Food and Drug Administration to approve the treatment in Amyotrophic lateral Sclerosis.